Perfil químico del "éxtasis". Derivados anfetamínicos de anillo sustituido en España
Keywords:
MDMA, Amphetamine derivatives, Chemical content, Ethnography, Illicit drugsAbstract
In the 1990s, the use of "ecstasy", a drug in form of pills that presumably contain MDMA (3,4-Methylenedioxymethamphetamine), has increased in Spain. In parallel, there has been an intense debate about the effects of this "new designer drug", the proximate and long-term health risks associated with its use, and its proper legal status. One of the main debate's issues is the real content (and the purity, adulteration and contamination) of the tablets and capsules sold and acquired as "ecstasy" on a daily basis. In this paper we compare data from the analysis of 89 samples of "ecstasy" obtained in 46 consumption sites throughout tbe country (demand side), with data from the analysis of the main police seizures in the same period (supply side). We found that "ecstasy" tablets in Spain usually contain one of three major types of active substances: Around 80 percent of samples contain one of four ring substituted amphetamine analogs (by order of frequency: MDMA>MDEA>MDA>MBDB); around 10 percent of cases contain mixtures of stimulants such as amphetamine, caffeine and methamphetamine, and the other 10 percent contain a variety of substances, often pharmaceuticals in tablet form that enter the market in the lower stages of distribution. MDMA and MDEA tablets appear to be a carefully made illicit product. Apart from the potential toxicity of those drugs, the adulteration and contamination of pills may pose less risk today than the high variation in the concentration of active principles and the growing number of counterfeit or "look alike" pills consumed as "ecstasy".
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).